Active Brain & Nervous System Infection & Immunity

Peripheral Modulators Of Neurodegeneration Along The Gut-brain Axis In Synucleinopathies

In plain English

AI plain-English summary

Immune cells in the gut are triggering the earliest stages of Parkinson’s disease, long before symptoms appear in the brain. This matters because Parkinson’s has traditionally been treated as a brain disorder, meaning therapies only arrive after significant damage is done. The researchers have discovered that gut-resident macrophages—a type of immune cell—become dysfunctional early on, allowing toxic clumps of alpha-synuclein protein to form in the gut and then spread along the vagus nerve into specific brain regions. The fundamental gap is that no one understands exactly how these peripheral immune cells in the gut communicate with neurons to drive that protein aggregation and region-specific brain cell death. If this succeeds, it could shift the entire therapeutic focus for Parkinson’s and related synucleinopathies from the brain to the gut. That would open the door to early intervention—treating or even preventing neurodegeneration by targeting gut immune cells years before motor symptoms appear. It could also yield new biomarkers for early diagnosis through blood or stool tests. This is primarily fundamental science, dissecting molecular and cellular mechanisms in mice and human cells. But similar work on gut-brain connections has already transformed treatments for conditions like irritable bowel syndrome and depression.

View original technical description
The gut-brain axis and neuroinflammation are emerging as key players in early stages of Parkinson’s disease (PD), challenging the neuron-centric view that PD is confined to the brain. We recently identified gut-resident macrophages as early instigators of PD-related pathologies. Dysfunctional gut-resident macrophages lead to exacerbated alpha-synuclein aggregation–a hallmark of PD and other synculeinopathies–and propagation along the gut-brain axis, leading to region-specific neurodegeneration in the brain.Our findings unlock therapeutic and biomarker opportunities beyond the brain; however, a fundamental knowledge gap remains: how do peripheral neuroimmune interactions in the gut mediate alpha-synuclein pathology and region-specific brain neurodegeneration? We assembled an interdisciplinary team to dissect neuroimmune mechanisms and their interactions with disease-specific alpha- synuclein aggregates in gut and brain. Integrating whole-body clearing, multi- omics, spatial transcriptomics, in vivo proteomics, advanced microscopy, functional studies in mice, and mechanistic studies in human cells. We aim to understand gut-brain immune crosstalk and its role in alpha-synuclein pathology on a molecular, cell-to-cell and organism-wide level.Insights will redefine neuroimmune modelling in PD, establishing how peripheral neuroimmune interactions contribute to disease-relevant protein aggregation and selective neurodegeneration. By expanding the therapeutic focus beyond the brain, this work could transform early intervention and disease-modifying strategies for PD and related disorders.

View the original record at the funder ↗

Researchers

Soyon Hong (EPMC Awardee)Tim Bartels (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Investigating the role of gut macrophages in mediating alpha-synuclein pathology in Parkinson’s disease
Role of neuro-immune-epithelial interactions in the initiation of Parkinson's Disease within the gut
Investigating protective mechanisms of gut bacteria in C. elegans models of Parkinson’s disease
Alpha-synuclein and mitochondrial dysfunction: key links between Gaucher’s disease and Parkinson’s?
Understanding the role of gut microbiota in Parkinson's using a C. elegans model

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.